SSRI and Buprenorphine

Butler Hospital

Status and phase: Completed; Phase 3

Conditions: Opiate Dependence; Depression

Treatments: Drug: escitalopram; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00475878

DA022207

0807-002

Details and patient eligibility

About

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Full description

Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Enrollment: 147 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• opiate dependence
• Ham-D > 14

Exclusion criteria

• no psychiatric contraindications to using escitalopram
• no medical contraindications to using escitalopram
• methadone dose < 30
• no current SSRI use

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

147 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: placebo

escitalopram

Active Comparator group

Treatment:

Drug: escitalopram